CD

Detlef Trefzger, Former CEO of Kuehne+Nagel International AG, Appointed Operating Advisor

Retrieved on: 
Mardi, novembre 7, 2023

NEW YORK, Nov. 7, 2023 /PRNewswire/ -- Clayton, Dubilier & Rice ("CD&R" or the "Firm") today announced the appointment of Detlef Trefzger as an Operating Advisor to CD&R funds.

Key Points: 
  • NEW YORK, Nov. 7, 2023 /PRNewswire/ -- Clayton, Dubilier & Rice ("CD&R" or the "Firm") today announced the appointment of Detlef Trefzger as an Operating Advisor to CD&R funds.
  • Dr. Trefzger also oversaw the $1.5B acquisition of Apex International, significantly expanding Kuehne+Nagel's air logistics footprint in Asia.
  • As of 1 November 2023, Detlef will become a Non-Executive Director at PSA International Pte Ltd ("PSAI").
  • Dr. Trefzger is a German citizen and holds a PhD in Business Management from the Vienna University of Economics and Business.

GetResponse Celebrates 25 Years of Innovation in Email Marketing

Retrieved on: 
Lundi, novembre 6, 2023

GDANSK, Poland, Nov. 6, 2023 /PRNewswire/ -- This month, GetResponse , a leading global email marketing platform, marks a significant milestone as it celebrates its 25th anniversary.

Key Points: 
  • GDANSK, Poland, Nov. 6, 2023 /PRNewswire/ -- This month, GetResponse , a leading global email marketing platform, marks a significant milestone as it celebrates its 25th anniversary.
  • GetResponse evolved from a local Polish startup into a global email marketing platform, boasting a team of 370 employees
    GetResponse played a vital role in shaping the early email marketing landscape, having launched the first autoresponder and officially registered the GetResponse domain in 1998.
  • Currently, GetResponse comprises three key solutions – the GetResponse platform, an email marketing solution for solopreneurs and SMBs; GetResponse MAX, an email and marketing automation solution tailored for mid-market organizations and high-volume senders; and the GetResponse affiliate and agency partner programs.
  • "It's been an astonishing ride so far, with GetResponse turning 25 this year," commented Simon Grabowski, Founder and CEO of GetResponse.

EQS-News: Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range

Retrieved on: 
Jeudi, octobre 26, 2023

Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range

Key Points: 
  • Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range
    The issuer is solely responsible for the content of this announcement.
  • Offering”) and a concurrent offering of ordinary shares in certain jurisdictions outside of the United States (the “European Private Placement”, and together, the “Global Offering”).
  • The Company’s ordinary shares are listed on the regulated market of Euronext Paris (“Euronext Paris”) under the symbol “ABVX”.
  • Morgan Stanley and Leerink Partners are acting as joint global coordinators for the proposed Global Offering and joint bookrunners for the U.S. Offering.

EQS-News: Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market 

Retrieved on: 
Jeudi, octobre 26, 2023

Offering”) and a concurrent offering of 1,626,040 ordinary shares in certain jurisdictions outside of the United States to certain investors (the “European Private Placement” and together with the U.S. Offering, the “Global Offering”).

Key Points: 
  • Offering”) and a concurrent offering of 1,626,040 ordinary shares in certain jurisdictions outside of the United States to certain investors (the “European Private Placement” and together with the U.S. Offering, the “Global Offering”).
  • The Global Offering is expected to close on October 24, 2023, subject to the satisfaction of customary closing conditions.
  • The ADSs have been approved for listing on the Nasdaq Global Market and are expected to begin trading on October 20, 2023 under the ticker symbol “ABVX”.
  • Morgan Stanley and Leerink Partners are acting as joint global coordinators for the proposed Global Offering and joint bookrunners for the U.S. Offering.

Morris State Bancshares Announces Quarterly Earnings and Declares Fourth Quarter Dividend

Retrieved on: 
Mercredi, octobre 25, 2023

The Company also announced diluted earnings per share of $2.12 for quarter, representing a 0.15% decrease from diluted earnings per share of $2.27 for the prior quarter.

Key Points: 
  • The Company also announced diluted earnings per share of $2.12 for quarter, representing a 0.15% decrease from diluted earnings per share of $2.27 for the prior quarter.
  • “In the third quarter, we generated net interest income of $12.9 million, just below the second quarter level of $13.2 million,” said Spence Mullis, Chairman and CEO.
  • “As projected, our margin compressed slightly in the third quarter, but we had solid loan growth of $25.4 million, or 10.0% annualized.
  • This loan growth bolstered our net interest income as it remained in line of that of the second quarter.

Chindata Group to Hold Extraordinary General Meeting of Shareholders

Retrieved on: 
Jeudi, octobre 19, 2023

BEIJING, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Chindata Group Holdings Limited (“Chindata Group” or the “Company”) (Nasdaq: CD), a leading carrier-neutral hyperscale data center solution provider in Asia-Pacific emerging markets, today announced that it has called an extraordinary general meeting of shareholders (the “EGM”), to be held on December 4, 2023 at 10:30 a.m. (Beijing time), at No.

Key Points: 
  • BEIJING, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Chindata Group Holdings Limited (“Chindata Group” or the “Company”) (Nasdaq: CD), a leading carrier-neutral hyperscale data center solution provider in Asia-Pacific emerging markets, today announced that it has called an extraordinary general meeting of shareholders (the “EGM”), to be held on December 4, 2023 at 10:30 a.m. (Beijing time), at No.
  • Shareholders of record at the close of business in the Cayman Islands on November 3, 2023 will be entitled to attend and vote at the EGM and any adjournment thereof.
  • The Company and certain of its directors and executive officers may, under SEC rules, be deemed to be “participants” in the solicitation of proxies from the shareholders with respect to the proposed Merger.
  • Further information regarding persons who may be deemed participants, including any direct or indirect interests they may have, is also set forth in the definitive proxy statement.

NImmune Biopharma Announces Positive Results of Omilancor in Ulcerative Colitis and Crohn’s disease at the American College of Gastroenterology 2023 Annual Scientific Meeting

Retrieved on: 
Lundi, octobre 23, 2023

Durable remission was induced in 38.5% of patients in the omilancor group versus 21.4% of patients given placebo (Δ=17.1, P = 0.05).

Key Points: 
  • Durable remission was induced in 38.5% of patients in the omilancor group versus 21.4% of patients given placebo (Δ=17.1, P = 0.05).
  • Title: Efficacy and Safety of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients with Crohn’s Disease.
  • Title: Transcriptional Analysis of Colonic Biopsies from Patients with Ulcerative Colitis Treated with Omilancor.
  • Additionally, the peer-reviewed accepted abstracts will be published verbatim in a special supplement to the October 2023 issue of The American Journal of Gastroenterology.

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease

Retrieved on: 
Lundi, octobre 23, 2023

Based on the results of the LIBERTY UC and LIBERTY CD studies, ZYMFENTRA demonstrated superiority in the primary endpoints of clinical remission (UC and CD) and endoscopic response (CD) compared to placebo as maintenance therapy after induction therapy of intravenous formulation of infliximab in patients with UC and CD, over a 54-week study period.

Key Points: 
  • Based on the results of the LIBERTY UC and LIBERTY CD studies, ZYMFENTRA demonstrated superiority in the primary endpoints of clinical remission (UC and CD) and endoscopic response (CD) compared to placebo as maintenance therapy after induction therapy of intravenous formulation of infliximab in patients with UC and CD, over a 54-week study period.
  • The overall safety profile of ZYMFENTRA was similar to that of placebo during maintenance period in both studies with no new safety signals seen.2,3
    “There remains an unmet need for patients who suffer from the day-to-day burden of living with moderately to severely active Crohn’s disease and ulcerative colitis,” said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA.
  • “As someone dedicated to improving the lives of patients with IBD, I am excited to see data supporting the efficacy and safety of a new formulation offering convenience and improved access to a well-known and proven drug,” said Dr. Andres Yarur of Cedars-Sinai Medical Center.
  • ZYMFENTRA will be under patent protection by 2037 for its dosage form and route of administration by 2040.

TransData® Finalizes Acquisition of ABACUS® Optical Probes Product Lines for Electric Meter Communications

Retrieved on: 
Jeudi, octobre 19, 2023

ABACUS Optical Probes provide the physical communication link between a computer data port and the infrared LEDs on electricity meters to obtain meter billing data, make programming changes and perform onsite diagnostics.

Key Points: 
  • ABACUS Optical Probes provide the physical communication link between a computer data port and the infrared LEDs on electricity meters to obtain meter billing data, make programming changes and perform onsite diagnostics.
  • Since their introduction in 1993, ABACUS Optical Probes have established a dedicated worldwide following based on their operational compatibility with most popular brands of electricity meters.
  • TransData's updated Windows 10 and Windows 11 compatible ABACUS Optical Probes are easily identified by their distinctive blue cable.
  • ABACUS Optical Probes can be purchased factory direct from TransData's website; or are stocked at over a dozen Amazon warehouse locations.

itel's, Yoni Epstein, receives National Honor for His Contribution to the Business Process Outsourcing Sector

Retrieved on: 
Mardi, octobre 17, 2023

He was awarded The Order of Distinction in the Commander class (CD) for his contribution to the business processing outsourcing sector.

Key Points: 
  • He was awarded The Order of Distinction in the Commander class (CD) for his contribution to the business processing outsourcing sector.
  • Epstein joins the ranks of other Jamaican greats who are considered to have made an impact beyond the call of service.
  • The awards ceremony took place during the National Heroes' Day ceremony and was televised across the nation.
  • Epstein has been a trailblazer in the business process outsourcing industry since he launched itel in Montego Bay in 2012.